Abstract 2306
Background
Nedaplatin (N) and nab-paclitaxel (nab-P) are efficacious in the treatment of non-small cell lung cancer (NSCLC), especially squamous cell lung cancer. Although a combination of N and nab-P was expected in the treatment of squamous cell lung cancer, there was no sufficient data.
Methods
The eligibility criteria were no prior chemotherapy; stage IIIB or stage IV squamous cell lung cancer; a performance status (PS) of 0–1; 75 > age > 20 years; and adequate hematologic, hepatic, and renal function. Patients (pts) received escalating doses of nab-P under a fixed dose of N (100 mg/m2, day 1) every 3 weeks in the phase I part. The initial dose of nab-P was 100 mg/m2 of day 1, 8 (level 1), and that of the next dose was 100 mg/m2 of day 1, 8, 15 (level 2). In the phase II part, pts received the recommended dose (RD) of N/nab-P. The primary endpoint was tumor response, which was measured using Response Evaluation Criteria in Solid Tumors 1.1.
Results
Five pts were enrolled in the phase I part. Three pts of level 1 have experienced no dose-limiting toxicities (DLTs). Two pts of level 2 have experienced DLTs, which were febrile neutropenia and the down of PS, respectively. Therefore, level 1 was determined to RD. 23 pts were enrolled in phase II part. Three pts in level 1 and 23 pts in phase II were evaluable, together. Partial response, stable disease, and progressive disease were noted in 21, 0, and 2 pts, respectively, yielding a response rate of 91.3% (95%confidence interval [CI]: 72.0–98.9). The median progression-free survival was 223 days (95%CI: 144–330), and the median survival time was 358 days (95%CI: 255–950). The grade 3 and 4 toxicities observed during all cycles were neutropenia (5 and 9 pts), anemia (6 and 2 pts), thrombocytopenia (5 and 3 pts). Grade 3 febrile neutropenia, pneumonia, and acute coronary syndrome were observed in 1, 2, and 1 pts, respectively. However, there was no treatment related death.
Conclusions
A combination of N (100 mg/m2, day 1) and nab-P (100 mg/m2, day 1, 8) every 3 weeks was the recommended dose. N/nab-P in this recommended dose appears to be efficacious and torerable in patients with untreated advanced squamous cell lung cancer.
Clinical trial identification
Legal entity responsible for the study
Kanto Respiratory Disease Study Group (KRSG)/JAPAN.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract